

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 January 2006 (26.01.2006)

PCT

(10) International Publication Number
WO 2006/008759 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/IN2005/000244

(22) International Filing Date: 20 July 2005 (20.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
709/CHE/2004 21 July 2004 (21.07.2004) IN

(71) Applicant (for all designated States except US): **CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS [CDFD]** [IN/IN]; Department of Biotechnology, Ministry of Science & Technology, Government of India, Nacharam, Hyderabad 500 076 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HASNAIN, Seyed, Ehtesham** [IN/IN]; Laboratory of Molecular and Cellular Biology, Centre for DNA Fingerprinting and Diagnostics [CDFD], Nacharam, Hyderabad 500 076 (IN). **CHAKHAIYAR, Prachee** [IN/IN]; Laboratory of Molecular and Cellular Biology, Centre for DNA Fingerprinting and Diagnostics [CDFD], Nacharam, Hyderabad 500 076 (IN). **NAGALAKSHMI, Yellajosyula** [IN/IN]; Mahavir Hospital and Research Centre, Hyderabad 500 004 (IN). **ARUNA, Bandi** [IN/IN]; Laboratory of Molecular and Cellular Biology, Centre for DNA Fingerprinting and Diagnostics [CDFD], Nacharam, Hyderabad 500 076 (IN). **MURTHY, Kollur, J., R.**, [IN/IN]; Mahavir Hospital and Research Centre, Hyderabad 500 004 (IN). **KOTOCH, Vishwa, M.**, [IN/IN]; Laboratory of Microbiology, Central Jalma Institute for Leprosy, Agra 282 001 (IN).

(74) Agents: **BHOLA, Ravi** et al.; K & S PARTNERS, 84-C, C6 LANE OFF CENTRAL AVENUE, SAINIK FARMS, NEW DELHI 110 062 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIGENIC PEPTIDES

(57) Abstract: The present invention relates to peptide antigens of SEQ ID Nos. 1 to 10; repeat motif Gly-X-Gly-Asn-X-Gly of SEQ ID No. 11; and a method of developing drug against tuberculosis, said method comprising steps of targeting the proposed drug towards peptide antigens of SEQ ID Nos. 1 to 11, and thereby developing the drug against tuberculosis.



WO 2006/008759 A2